REPL — Replimune Group, Inc. Stock Price, Chart & AI Report

Negative Oct 2, 2026 • 18:44 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th

A class action lawsuit has been filed against Replimune Group Inc. for allegedly making materially false statements regarding its Biologics License Application (BLA). The lawsuit claims the company failed to disclose that FDA study design concerns were not addressed and that submitted data from an early analysis included only 40 of 400 planned patients, likely causing FDA rejection of the BLA. Investors who purchased securities between October 20, 2025 and April 10, 2026 can apply to be lead plaintiff by October 5, 2026.

REPL class action lawsuit Biologics License Application FDA rejection securities fraud misleading statements investor losses

Sentiment note

The company faces a class action lawsuit alleging material misstatements and non-disclosure of adverse information regarding FDA regulatory concerns and insufficient clinical trial data, which resulted in likely BLA rejection and investor losses.

Negative Sep 15, 2026 • 22:13 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

Pomerantz Law Firm has filed a class action lawsuit against Replimune Group, Inc. following the FDA's rejection of the company's Biologics License Application for RP1 in combination with nivolumab on April 10, 2026. The FDA cited deficiencies in clinical studies and stated the evidence did not meet approval standards. The stock price fell 19.46% on the announcement and an additional 64.29% days later, totaling an 83.75% decline from $4.76 to $1.70 per share. Investors who purchased securities during the class period have until October 5, 2026, to request Lead Plaintiff status.

REPL FDA rejection Biologics License Application class action lawsuit securities fraud clinical trial deficiencies stock price decline RP1

Sentiment note

The company faced a significant FDA rejection of its lead drug candidate's BLA, resulting in a dramatic stock price collapse of 83.75% over three trading days. The FDA identified serious deficiencies in clinical trial design and data sufficiency, and the company is now subject to a class action lawsuit alleging securities fraud and unlawful business practices.

Negative Sep 15, 2026 • 22:11 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY

Pomerantz Law Firm has filed class action lawsuits against ARS Pharmaceuticals, Inc. and other companies for alleged securities fraud. ARS's stock fell 23.91% after the company failed to secure expanded insurance coverage for its epinephrine nasal spray (neffy) through CVS Caremark by the July 1, 2026 deadline. Investors have until October 5, 2026 to join the class action.

SPRY ALAR REPL class action lawsuit securities fraud ARS Pharmaceuticals stock price decline insurance coverage

Sentiment note

Subject of a class action lawsuit filed by Pomerantz Law Firm, indicating alleged securities violations or corporate misconduct.

Negative Sep 14, 2026 • 16:57 UTC GlobeNewswire Inc. • Levi & Korsinsky, Llp

REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky

A securities class action has been filed against Replimune Group, Inc. for allegedly failing to disclose regulatory concerns about its RP1 trial design to shareholders. The lawsuit claims the company built its regulatory strategy around single-arm trial designs that the FDA had already questioned, including response criteria inconsistent with RECIST v1.1 standards. Investors who purchased REPL shares between October 20, 2025 and April 10, 2026 experienced significant losses, with the stock declining 84.16% during the class period.

REPL securities class action clinical trial design FDA regulatory concerns disclosure violations shareholder losses RP1 drug candidate single-arm trial

Sentiment note

The company faces a securities class action lawsuit alleging material non-disclosure of FDA regulatory concerns regarding RP1 trial design deficiencies. Stock declined 84.16% during the class period, and allegations suggest management misrepresented the adequacy of trial designs that regulators had already scrutinized.

Negative Sep 10, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Replimune Group, Inc. alleging that the company made false and misleading statements regarding its FDA submission for RP1-104. The complaint claims Replimune failed to address FDA study design concerns and submitted data from an early analysis with only 40 patients instead of the planned 400, which likely led to BLA rejection. Investors who purchased securities between October 20, 2025 and April 10, 2026 are encouraged to join the case.

REPL class action lawsuit securities fraud FDA submission BLA rejection investor harm misleading statements clinical trial data

Sentiment note

The company is accused of making false and misleading statements about its business operations and FDA submission process. Allegations include failure to disclose study design concerns, submission of incomplete trial data (10% of planned enrollment), and deficiencies likely to result in FDA rejection of its BLA, indicating significant regulatory and operational failures.

Negative Sep 3, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Replimune Group, Inc. alleging securities fraud. The complaint claims the company made false statements about its business operations and failed to disclose FDA study design concerns and deficiencies in its BLA submission. The lawsuit covers investors who purchased Replimune securities between October 20, 2025 and April 10, 2026.

REPL class action lawsuit securities fraud FDA BLA submission investor harm false statements RP1-104

Sentiment note

The company is the subject of a securities fraud class action lawsuit alleging material misstatements and omissions regarding FDA study design concerns and deficiencies in clinical trial data submission. These allegations suggest serious regulatory and operational failures that caused investor harm.

Negative Aug 31, 2026 • 18:50 UTC GlobeNewswire Inc. • Glancy Prongay Wolke & Rotter Llp

Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP announced a class action lawsuit against Replimune Group, Inc. for alleged securities fraud. The company made misleading statements about its FDA drug application (RP1 BLA) between October 2025 and April 2026. The FDA rejected the application on April 10, 2026, citing undisclosed study design deficiencies and insufficient patient data (40 of 400 planned patients), causing the stock to plummet 19.46% on the day and an additional 64.29% decline by April 13, 2026. Investors who purchased shares during the class period are urged to file lead plaintiff motions by October 5, 2026.

REPL securities fraud class action lawsuit FDA rejection BLA (Biologics License Application) RP1 melanoma treatment stock price decline

Sentiment note

The company faces a securities fraud class action lawsuit for making materially false and misleading statements about its FDA drug application. The FDA rejected the BLA citing undisclosed study design concerns and insufficient patient data. The stock experienced severe losses (19.46% on April 10 and 64.29% by April 13, 2026), indicating significant investor harm and loss of confidence in the company's disclosures and drug development program.

Negative Aug 27, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Replimune Group, Inc. alleging that the company made false and misleading statements regarding its FDA submission for RP1-104. The complaint claims Replimune failed to disclose study design concerns from the FDA and submitted data from an early analysis with only 40 patients instead of the planned 400, which likely caused FDA rejection of the BLA. Investors who purchased securities between October 20, 2025 and April 10, 2026 are eligible to join the case.

REPL class action lawsuit securities fraud FDA rejection BLA submission RP1-104 investor harm misleading statements

Sentiment note

The company is accused of making false and misleading statements about its business operations and FDA submission process. Allegations include failure to disclose FDA concerns and submitting incomplete clinical trial data (10% of planned enrollment), which likely led to FDA rejection of the BLA. This represents significant regulatory and legal risk to investors.

Negative Aug 5, 2026 • 21:52 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire is investigating Replimune Group Inc. following FDA briefing documents that deemed the company's mid-stage study for its skin cancer drug RP1 as 'not interpretable.' The FDA assessment raised concerns about the study's ability to verify efficacy results. Following the news on July 28, 2026, Replimune's stock price dropped 37.89% in intraday trading.

REPL FDA approval drug trial securities investigation stock price decline class action stockholder rights

Sentiment note

FDA deemed the company's lead drug trial as 'not interpretable' with concerns about efficacy verification, leading to a significant 37.89% stock price drop. The company is under investigation for potential securities law violations.

Positive Jul 30, 2026 • 22:15 UTC GlobeNewswire Inc. • Na

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

Replimune's FDA advisory committee voted 10-3 that efficacy results from the IGNYTE study for RP1 (in combination with nivolumab) are evaluable and clinically meaningful for treating advanced melanoma in anti-PD-1 therapy-resistant patients. The FDA's target action date for the BLA resubmission is August 2, 2026.

REPL RP1 vusolimogene oderparepvec advanced melanoma oncolytic immunotherapy FDA approval IGNYTE study nivolumab

Sentiment note

The advisory committee voted favorably (10-3) that RP1's efficacy results are evaluable and clinically meaningful, representing a significant milestone toward FDA approval. The positive committee recommendation and imminent FDA action date (August 2, 2026) indicate strong progress in the regulatory pathway for the company's lead product candidate.

Negative Jul 30, 2026 • 21:48 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire is investigating Replimune Group Inc. following FDA briefing documents that deemed the company's mid-stage study for its skin cancer drug RP1 as 'not interpretable.' The FDA assessment raised concerns about the study's ability to verify efficacy results. Following the announcement on July 28, 2026, Replimune's stock price dropped 37.89% in intraday trading.

REPL FDA approval clinical trial securities investigation stock price decline drug development skin cancer treatment

Sentiment note

FDA deemed the company's lead drug trial as 'not interpretable' with concerns about efficacy verification, leading to a significant 37.89% stock price drop. The company is under investigation for potential securities law violations.

Negative May 18, 2026 • 01:49 UTC GlobeNewswire Inc. • Schall Law Firm

REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm is investigating Replimune Group, Inc. for potential securities law violations related to allegedly false or misleading statements. The company received a complete response letter from the FDA regarding its BLA for RP1 in combination with nivolumab for advanced melanoma treatment, citing disagreement over data suitability. Following this announcement on April 10, 2026, Replimune's stock price fell approximately 64.3% on April 13, 2026.

REPL securities fraud FDA rejection BLA (Biologics License Application) stock decline shareholder litigation RP1 nivolumab

Sentiment note

The company received an FDA complete response letter indicating disagreement over submitted data for its drug candidate, resulting in a 64.3% stock price decline and triggering a fraud investigation by a major shareholder litigation firm, indicating significant setback in clinical development and investor confidence.